Placental transfer of anti-Group B Streptococcus IgG antibody subclasses from HIV-infected and uninfected women to their uninfected infants by Mehring-Le Doare, KEK et al.
AIDS
 
Placental transfer of anti-Group B Streptococcus IgG antibody subclasses from HIV-
infected and uninfected women to their uninfected infants
--Manuscript Draft--
 
Manuscript Number: AIDS-D-15-00687R1
Full Title: Placental transfer of anti-Group B Streptococcus IgG antibody subclasses from HIV-
infected and uninfected women to their uninfected infants
Article Type: Concise Communication (Clinical)
Keywords: Group B Streptococcus, antibody, HIV, neonates, placental transfer
Corresponding Author: Kirsty Le Doare, MBBS PhD
Imperial College London
London, UNITED KINGDOM
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Imperial College London
Corresponding Author's Secondary
Institution:
First Author: Kirsty Le Doare, MBBS PhD
First Author Secondary Information:
Order of Authors: Kirsty Le Doare, MBBS PhD
Stephen Taylor, PhD
Lauren Allen, BSc
Andrew Gorringe, PhD
Paul Heath, FRCPCH
Beate Kampmann, PhD
Anneke Hesseling, PhD
Christine E. Jones, PhD
Order of Authors Secondary Information:
Manuscript Region of Origin: SOUTH AFRICA
Abstract: Objectives: Placental antibody transfer is impaired in the context of HIV infection, which
may render HIV-exposed, uninfected infants vulnerable to Group B streptococcus
(GBS) disease. The GBS antibody response predominately consists of IgG2 antibody.
Thus we determined whether concentration and placental transfer of anti-GBS
antibody-subclasses was altered in HIV-infected compared to HIV-uninfected mothers
Design: A retrospective analysis of anti-GBS antibody subclasses in 38 HIV-infected
and 33 HIV-uninfected mothers and their uninfected infants.
Methods:  Sera were analysed using a novel flow cytometric assay that quantified
binding of IgG1, IgG2, IgG3 and IgG4 to serotype (ST) Ia, STIII and STV GBS bacteria.
Results: IgG2 binding to GBS ST1a and V was lower in HIV-infected women compared
to uninfected women. Moreover, IgG2 binding to GBS ST1a was also lower in HIV-
exposed, uninfected infants compared to unexposed infants. However, there were no
statistically significant differences in the transplacental transfer ratio
of IgG2 for any GBS serotype. The transplacental transfer of total IgG was reduced for
GBS STIII and V and IgG1 subclass for STIII; placental transfer of all other subclasses
was comparable in HIV-affected and HIV-unaffected pregnancies.
Conclusion: Anti-GBS IgG2 placental transfer is not affected by HIV infection. This is
important for functional antibody against the capsular polysaccharide of GBS and
provides confidence that maternal GBS vaccination may result in functional activity in
HIV infected and uninfected women.
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Response to Reviewer comments 
 
Reviewer #2 Many thanks for your review, we have addressed your queries and suggestions as outlined below: 
 Most of the method section is the same 
as the method section in ref# 11 or 15 
and all the technical and statistical parts 
can be shorter by referring to one of 
these references 
We have amended as you suggest and 
referenced the original paper: 
“Deposition of total IgG and IgG1, IgG2, 
IgG3 and IgG4 anti-GBS antibody 
subclasses onto the surface of 
formaldehyde-fixed GBS bacteria was 
measured using a flow cytometric assay 
performed in 96-well microtitre plates 
as previously described[10].” 
P6 line 90-93 
 Results p.6 line 120-121 suggests that 
"concentrations of anti-GBS IgG1 and 
IgG3 in mothers and infants were higher 
than concentrations of IgG2 for all GBS 
serotypes." Yet, from the figure it seems 
that IgG2 for HIV-unexposed infants was 
higher for IgG2 than IgG3 for both STIa 
and STIII and the same for HIV+ mothers 
for STIa. 
Thank you for pointing out this 
oversight. The sentence has been 
amended: “Concentrations of anti-GBS 
IgG1 in mothers and infants were higher 
than concentrations of IgG2 for all GBS 
serotypes, independent of HIV status 
(Figure 1).” 
P8 line130-131 
 Results p.7 line 135-136. Why a P value 
of 0.05 is called "trend"? 
We took p value of less than 0.05 to be 
significant.  
This has been added to the methods 
section. However, this p value was 
actually 0.047 and we had rounded it 
up. We have amended the sentence as 
follows: “had significantly higher 
concentrations of IgG2 than HIV-
infected women (p=0.047) 
P8 line 140 
 Results p.7 line 137-139. The sentence is 
not clear as "HIV- uninfected infants" 
seems to be compared to "HIV- 
Thank you for pointing out this typing 
error. This has now been amended: 
“HIV-unexposed infants” 
P 8 line 137 
Response to reviewers
uninfected infants". 
 Discussion p.8 line 160-162. There is no 
mention in the current study for such 
findings. It seems that it was reported in 
a previous publication (ref# 11 or 15) 
and if so it should be cited 
This finding is highlighted in Table 1 Table 1 
 Discussion p.8 line 162-164. Need to add 
"except for IgG1 for STIII" (the P value 
for this specific subclass was 0.04). 
This has been added: “The observation 
that there is no difference in the 
proportion of IgG subclass placental 
transfer (except for IgG1 for STIII)” 
P9 line 176- 
 Discussion p. 8-9 line 168-173. A further 
explanation of this statement would be 
appreciated especially for STIII. This 
serotype cause 84.4% of LOS (line 178) 
and yet there are no statistical 
differences in all IgG subtype levels for 
this serotype between HIV-exposed or 
unexposed infants (figure). Thus, it is not 
clear why the reduced total antibodies 
from the HIV infected mother will affect 
the HIV-exposed infant more than the 
unexposed infant when both have 
almost the same amount of all IG 
subclasses. 
We have added further explanation:” It 
may alternatively be due to the poor 
function of Th1 and T helper cellular 
response and function of antibody in the 
context of HIV-infection[15].” 
P10 line 180-182 
 References p12 line 263. Ref # 10 Please 
add the volume and pages. 
This has been corrected  
 The same for Ref # 14. This has been corrected  
 References: references 11 and 15 are 
the same reference. 
The correct reference has now been 
added 
Ref 10 
Reviewer #3 This paper described the levels of anti-
GBS antibody-subclasses in a cohort of 
HIV-infected and HIV-uninfected women 
and their infants and the transplacental 
Many thanks for your review. We have 
amended and improved the text as you 
suggest. 
 
antibody transfer of each subclass. The 
paper is concise and well written and 
findings are of interest given the high 
risk of GBS among HIV-exposed infants. 
 No correction was made for multiple 
comparisons, although given the 
number of GBS serotype and IgG 
combinations being compared, it seems 
this would have been appropriate. Could 
the authors comment on why this was 
not done and whether / how it would 
have altered the results? 
Because the numbers in each serotype 
were relatively small, multiple 
comparisons were not possible. 
 
 The manuscript does not describe the 
ART treatment status of mothers with 
HIV in the cohort, nor the ranges of HIV 
viral loads or CD4 counts. As HIV viral 
load has been shown to be associated 
with transplacental antibody transfer in 
previous studies and ART may improve 
transplacental antibody transfer, this 
information is important to put these 
results in context. 
This information is available in the 
original manuscript (reference 14): “The 
demographic details, CD4 count, viral 
load and antiretroviral medication have 
been previously described[14]. ” 
P6 line 82-84 
 Line 114 states missing data were 
excluded from the analysis, but no 
information is provided as to how 
complete the data were. It would be 
helpful to add n's to the figure and table 
(or give range of % missingness in results 
section).  
We have added this to the results 
section:” The paired sera from 71 
mother-infant dyads (38 HIV-infected 
mothers and their uninfected infants 
and 33 HIV-uninfected mothers and 
their infants) at birth were available for 
analysis of total IgG, IgG1 and IgG2 for 
all serotypes. For serotypes ST1a and 
STV, sufficient sera was available from 
60 mother-infant pairs to analyse 
subclasses IgG3 and IgG4.  Sufficient 
P7 line 118-123 
sera was available from 40 mother-
infant pairs for analysis of  IgG3 and 
IgG4 for STIII.” 
 Discrepancy between results section and 
Figure 1:  
The text (line 129) states that in HIV-
unexposed infants there was a 
significantly LOWER concentration of 
IgG2, but the figure appears to show 
they had a HIGHER concentration of 
IgG2 (as well as IgG4). Please clarify 
which is correct.  
 
Thank you for highlighting this typing 
error. The sentence correctly reads: 
“HIV-unexposed infants had higher 
concentrations of anti-STV IgG3 
antibody compared to HIV-exposed 
infants (p=0.039).” 
P8 line 141-143 
 The text (line 134) says there was a 
trend toward higher IgG1 
concentrations among HIV-infected 
women (p=0.05), but the figure indicates 
the difference was significant with 
p<0.05. Please clarify which is correct.  
The p value was actually p=0.0487, and 
was rounded up in the text. The actual p 
value “p=0.0487” has now been inserted 
into the tex 
 
 The text further states (line 130) "In 
addition, we noted a trend toward 
higher concentrations of anti-STIa IgG1 
and IgG3 but this did not reach 
significance", but the figure shows anti-
STIa IgG1 was lower but anti-STIa IgG3 
was higher in HIV-exposed uninfected 
infants. 
This now correctly reads:” In addition, 
we noted a trend towards higher 
concentrations of anti-STIa IgG1 and 
lower concentration of IgG3 but this did 
not reach statistical significance (Figure 
1). “ 
P8 line 134-136 
 Line 83: "38 HIV-infected and 33-HIV 
uninfected mothers and infants" is a 
little unclear as none of the infants were 
HIV-infected. I suggest rephrasing as "38 
HIV-infected and 33 HIV-uninfected 
mothers and their respective uninfected 
This line now reads:” Paired sera from 
38 HIV-infected and 33 HIV-uninfected 
mothers and their uninfected infants 
were available to analyze 
immunoglobulin subclasses.” 
P6 Line 86-87 
infants" or similar. 
 Stata is made by StataCorp, College 
Station, Texas 
(StataCorp 2013, College Station, Texas) Line 106 
 Line 126: Specify what numbers 
contained in brackets (e.g. for IgG2 [1.6-
3.3]) represent - the 95% confidence 
interval? 
95% Confidence Interval (CI) Line 131 
Reviewer #5: Interesting study, addressing both IgG 
sub-classes and GBS serotypes and 
transplacental transfer. The manuscript 
is well written and is one of several from 
the authors from the same cohort. A 
brief description of demographics of 
mothers and infant should, however, 
either briefly be given or referenced. 
The study adds to the increasing body of 
evidence supporting maternal 
immunization 
Many thanks, we have referenced the 
original study which gives the 
demographic description of the cohort:” 
The demographic details, CD4 count, 
viral load and antiretroviral medication 
has been previously described[14].” 
Line 81 
 
 
Abstract  
Objectives: Placental antibody transfer is impaired in the context of HIV infection, 
which may render HIV-exposed, uninfected infants vulnerable to Group B 
streptococcus (GBS) disease. The GBS antibody response predominately consists of 
IgG2 antibody. Thus we determined whether concentration and placental transfer of 
anti-GBS antibody-subclasses was altered in HIV-infected compared to HIV-
uninfected mothers 
Design: A retrospective analysis of anti-GBS antibody subclasses in 38 HIV-infected 
and 33 HIV-uninfected mothers and their uninfected infants. 
Methods:  Sera were analysed using a novel flow cytometric assay that quantified 
binding of IgG1, IgG2, IgG3 and IgG4 to serotype (ST) Ia, STIII and STV GBS bacteria.  
Results: IgG2 binding to GBS ST1a and V was lower in HIV-infected women compared 
to uninfected women. Moreover, IgG2 binding to GBS ST1a was also lower in HIV-
exposed, uninfected infants compared to unexposed infants. However, there were 
no statistically significant differences in the transplacental transfer ratio  
of IgG2 for any GBS serotype. The transplacental transfer of total IgG was reduced 
for GBS STIII and V and IgG1 subclass for STIII; placental transfer of all other 
subclasses was comparable in HIV-affected and HIV-unaffected pregnancies.  
Conclusion: Anti-GBS IgG2 placental transfer is not affected by HIV infection. This is 
important for functional antibody against the capsular polysaccharide of GBS and 
provides confidence that maternal GBS vaccination may result in functional activity 
in HIV infected and uninfected women.  
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Abstract  28 
Objectives: Placental antibody transfer is impaired in the context of HIV infection, 29 
which may render HIV-exposed, uninfected infants vulnerable to Group B 30 
streptococcus (GBS) disease. The GBS antibody response predominately consists of 31 
IgG2 antibody. Thus we determined whether concentration and placental transfer of 32 
anti-GBS antibody-subclasses was altered in HIV-infected compared to HIV-33 
uninfected mothers 34 
Design: A retrospective analysis of anti-GBS antibody subclasses in 38 HIV-infected 35 
and 33 HIV-uninfected mothers and their uninfected infants. 36 
Methods:  Sera were analysed using a novel flow cytometric assay that quantified 37 
binding of IgG1, IgG2, IgG3 and IgG4 to serotype (ST) Ia, STIII and STV GBS bacteria.  38 
Results: IgG2 binding to GBS ST1a and V was lower in HIV-infected women compared 39 
to uninfected women. Moreover, IgG2 binding to GBS ST1a was also lower in HIV-40 
exposed, uninfected infants compared to unexposed infants. However, there were 41 
no statistically significant differences in the transplacental transfer ratio  42 
of IgG2 for any GBS serotype. The transplacental transfer of total IgG was reduced 43 
for GBS STIII and V and IgG1 subclass for STIII; placental transfer of all other 44 
subclasses was comparable in HIV-affected and HIV-unaffected pregnancies.  45 
Conclusion: Anti-GBS IgG2 placental transfer is not affected by HIV infection. This is 46 
important for functional antibody against the capsular polysaccharide of GBS and 47 
provides confidence that maternal GBS vaccination may result in functional activity 48 
in HIV infected and uninfected women.  49 
 50 
Key Words: Group B Streptococcus, antibody, HIV  51 
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Introduction 52 
Opsonophagocytosis of Group B Streptococcus (GBS) is mediated predominately by 53 
the immunoglobulin G2 (IgG2) subclass [1], which is poorly transported across the 54 
placenta compared to IgG1[2, 3]. This may reflect the lower affinity of IgG2 for the 55 
FcRn receptors on syncytiotrophoblasts of placental cells as compared with the other 56 
subclasses of IgG[4, 5]. Studies comparing maternal and infant antibody 57 
concentrations demonstrate that anti-GBS capsular antibody is transferred across 58 
the placenta with a high degree of efficiency [6]. However, the proportionally higher 59 
concentration of antibody in infant compared to maternal serum at birth is thought 60 
to be mainly due to excess fetal IgG1[2]. It has been demonstrated for GBS serotype 61 
(ST) Ia and STIII that not only is total anti-GBS antibody concentration lower in GBS-62 
infected infants than in infants without infection born to colonized mothers [7, 8], 63 
but that IgG2 is also lower in infants with GBS infection[9]. Recent studies have 64 
shown that maternal and placental transfer of total anti-GBS antibody is reduced in 65 
the context of maternal HIV-infection[10, 11]. This might explain the greater 66 
reported incidence of early, and especially late onset, GBS observed amongst HIV-67 
exposed, uninfected infants compared to unexposed infants[12]. A West African 68 
study identified hypergammaglobulinaemia as a risk factor for reduced placental 69 
transfer of IgG subclasses and this might be a further contributing factor to the 70 
observed excess of GBS morbidity amongst HIV-exposed infants[13].  Thus, we 71 
compared total and subclass anti-GBS antibody placental transfer in HIV-infected and 72 
HIV-uninfected South African women.  73 
 74 
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Methods 75 
Samples were collected from mothers and infants enrolled in a cohort study 76 
investigating the influence of maternal HIV and mycobacterial sensitization on infant 77 
immune responses to BCG vaccination carried out between 2009 and 2011[14]. The 78 
demographic details, CD4 count, viral load and antiretroviral medication have been 79 
previously described[14]. Informed consent was obtained from all mothers 80 
participating in the study. The study was approved by the Universities of Cape Town 81 
(382/2008) and Stellenbosch (N08/10/278), South Africa, and the National Health 82 
Service Research Ethics Committee, England (07/H0720/178).  83 
 84 
Paired sera from 38 HIV-infected and 33 HIV-uninfected mothers and their 85 
uninfected infants were available to analyze immunoglobulin subclasses. Deposition 86 
of total IgG and IgG1, IgG2, IgG3 and IgG4 anti-GBS antibody subclasses onto the 87 
surface of formaldehyde-fixed GBS bacteria was measured using a flow cytometric 88 
assay performed in 96-well microtitre plates as previously described[10]. Mouse 89 
monoclonal antibodies: 4E3 anti-human IgG1 H&L, HP6014 anti-human IgG2 fd 90 
gamma, HP6050 anti-human IgG3 hinge heavy chain and mouse HP6025 anti-human 91 
IgG4 Fc (FITC) (Life Technologies) (1:500) in blocking buffer were added and samples 92 
incubated for 20 minutes at 4°C. Assays were analyzed using a Beckman Coulter Cyan 93 
flow cytometer equipped with a Cytek 96-well microtitre plate loader. A 94 
Fluorescence Index (FI) was calculated for each sample, which involved the 95 
multiplication of the percentage of bacteria in the horizontal gate (%-gated), by the 96 
mean fluorescence of that population (X-mean). The final result for each test was 97 
expressed as the average FI of duplicate test samples minus the average FI of the 98 
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bacteria and conjugate-only control. A standard unit (SU) measurement for each 99 
serum sample was then calculated by comparing to the serum FI response obtained 100 
with the positive control serum for each serotype which was given an arbitrary value 101 
of 1000 (kind gift from Professor Carol Baker, Baylor College of Medicine, Texas) to 102 
give a result in SU/mL.  103 
 104 
Statistical analyses were completed using STATA version 12 (StataCorp 2013, College 105 
Station, Texas) and GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, 106 
California).  The sample size was calculated to demonstrate a 50% difference in IgG 107 
subclass concentrations between HIV-exposed and HIV-unexposed infants with the 108 
predefined assumption that antibody subclass concentrations would be lower in HIV-109 
exposed infants. Using an α error of 5%, 80% test power and a 95% confidence 110 
interval, the sample size ranged from 10- 30 in each group. Placental transfer was 111 
defined as the ratio of infant-to-mother GBS IgG concentration at birth. Missing data 112 
were excluded from analysis. We considered p values of <0.05 as statistically 113 
significant. 114 
 115 
Results 116 
The paired sera from 71 mother-infant dyads (38 HIV-infected mothers and their 117 
uninfected infants and 33 HIV-uninfected mothers and their infants) at birth were 118 
available for analysis of  total IgG, IgG1 and IgG2 for all serotypes. For serotypes ST1a 119 
and STV, sufficient sera was available from 60 mother-infant pairs to analyse 120 
subclasses IgG3 and IgG4.  Sufficient sera were available from 40 mother-infant pairs 121 
for analysis of  IgG3 and IgG4 for STIII. 122 
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 123 
Antibody subclass concentrations 124 
Concentrations of anti-GBS IgG1 in mothers and infants were higher than 125 
concentrations of IgG2 for all GBS serotypes, independent of HIV status (Figure 1). 126 
 127 
For STIa, HIV-uninfected women had significantly higher geometric mean 128 
concentration (GMC) of subclass IgG2 and IgG4 than HIV-infected women (IgG2 2.3 129 
[95% Confidence Interval (CI) 1.6-3.3] vs. 5.9 [4.0-8.9] SU/mL, p=0.02; IgG4 1.8 [0.9-130 
3.6] vs. 18.6 [6.0-57.8] SU/mL, p=0.03) but comparable concentrations of IgG1 and 131 
IgG3 (Figure 1). In HIV-unexposed compared to HIV-exposed, uninfected infants, 132 
there was a significantly higher concentration of IgG2 (p=0.03) and IgG4 (p=0.03). In 133 
addition, we noted a trend towards higher concentrations of anti-STIa IgG1 and 134 
lower concentration of IgG3 but this did not reach statistical significance (Figure 1).   135 
 136 
For STV, HIV-infected women had a trend towards higher concentrations of IgG1 137 
than HIV-uninfected women (p=0.049) and HIV-uninfected women had significantly 138 
higher concentrations of IgG2 than HIV-infected women (p=0.047), although the 139 
concentration of IgG2 was low in both groups. HIV-unexposed infants had higher 140 
concentrations of anti-STV IgG3 antibody compared to HIV-exposed infants 141 
(p=0.039). There was no statistical difference between HIV-exposed, uninfected 142 
infants and HIV-unexposed infants for any of the other IgG subclasses (Figure 1).  143 
 144 
There was no significant difference between anti-STIII IgG subclasses in HIV-infected 145 
and HIV-uninfected women and HIV-exposed, uninfected and HIV-unexposed 146 
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infants.  147 
 148 
Placental transport of total GBS antibody 149 
Total IgG transplacental antibody transfer ratio (TPR) was reduced in HIV-infected 150 
compared to HIV-uninfected women for GBS STIII (0.6 [0.3-1.1] vs. 1.3 [0.8-2.3] 151 
SU/mL, p=0.04) and STV (1.2 [0.7-1.6] vs. 2.0 [1.1-3.0] SU/mL, p=0.04) but not for 152 
STIa. (Table 1). There was no association between CD4 count or viral load and TPR. 153 
 154 
Placental transport of subclasses GBS-antibody 155 
TPR of IgG1 was decreased to HIV-exposed infants compared to HIV-unexposed 156 
infants (0.4 (0.1-1.4) vs. 1.3 (0.7-2.5) SU/mL; p=0.04) for STIII but not for STIa or STV, 157 
(Table 1). The TPR for IgG2 was unaffected by maternal HIV infection status for any 158 
serotype. There were no statistical differences between antibody TPR for any other 159 
subclass or any other serotype of GBS between groups. 160 
 161 
DISCUSSION 162 
Our findings demonstrate that whilst total transplacental transfer ratios are reduced 163 
in HIV-infected mothers for GBS STIII and V, the proportion of individual subclasses 164 
transferred from mother to infant is unaffected by maternal HIV infection, with the 165 
exception of IgG1 to GBS STIII. Importantly, there was no difference in the placental 166 
transfer of IgG2 that bound to any of the GBS serotypes.   167 
 168 
HIV-exposed, uninfected infants may be at increased risk of GBS infection, in 169 
particular late onset disease[10, 12] The observation that there is no difference in 170 
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the proportion of IgG subclass placental transfer (except for IgG1 for STIII) may mean 171 
that HIV-exposed, uninfected infants are at increased risk of disease as a result of 172 
their mother’s reduced total antibodies that bind to GBS bacteria, rather than a 173 
selective deficit in IgG2 transfer. It may alternatively be due to impaired B cell 174 
function in the context of HIV infection that results from poor function of T helper 175 
cellular response and function of antibody in the context of HIV-infection [15]. 176 
 177 
The fact that IgG2 surface deposition was lower in HIV-exposed infants to STIa and in 178 
women to STV in HIV-infected women may indicate reduced antibody function due 179 
to HIV-infection. In this study we were unable to assess the opsonophagoyctic ability 180 
of the antibody which would provide additional information on the functional ability 181 
of antibody to protect from GBS infection. In studies of pneumococcal vaccination, 182 
opsonophagocytosis was impaired in HIV-infected compared to HIV-uninfected 183 
individuals and the same may be true of GBS [16].  184 
 185 
The serotypes we have selected in this study represent 77% of colonizing strains in 186 
South African pregnant women (STIII, 33%; STIa, 39%; STV, 12%[17]). They also 187 
represent 86.1% of early onset (EOS) GBS disease and 100% of late onset disease 188 
(LOS) (STIII 57.7% EOS, 84.4% LOS; STIa 22.6%/ 13.9%; STV 5.8%/1.9%[18]). Thus, the 189 
serotype-specific antibody observed corresponds to the predominant colonizing and 190 
disease-causing serotypes in South Africa. 191 
 192 
Although patients with HIV disease develop high levels of total IgG in serum soon 193 
after infection [19], the IgG1 subclass is preferentially increased, whereas levels of 194 
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total IgG2 may be normal or decreased [20]. We confirmed the relatively similar 195 
concentration of IgG2 antibody that binds to GBS STIII in the sera of HIV-infected and 196 
HIV-uninfected women. IgG2 responses to the bacterial capsular polysaccharide in 197 
humans may be driven in part by IFN-y production[21], which may be impaired 198 
during HIV-infection[22]. However, HIV-infected patients in our cohort showed no 199 
selective deficit in IgG2 production. The differences in subclass distribution by GBS 200 
serotype may be as a result of different reactivity of the different serotypes in our 201 
assay. However, comparison with the larger study demonstrated good correlation 202 
between total antibody concentrations for all serotypes tested[10].  203 
 204 
Maternal HIV infection has been associated with reduced placental transfer of 205 
antibodies against several common viral and bacterial antigens[23, 24]. Additionally, 206 
the finding that HIV-exposed, uninfected infants are more likely to have sub-207 
protective antibody levels to vaccine preventable diseases means that these infants 208 
are likely to be more prone to these diseases in early childhood. Our finding that the 209 
placental transfer of IgG2 subclass, important for the opsonisation and killing of GBS 210 
was not impaired, indicates potential for a maternal vaccine to boost both maternal 211 
and infant immunity in areas of high HIV-prevalence. 212 
 213 
Our sample size was limited and we are not able to draw conclusions on other 214 
possible effects of HIV-infection on placental transfer. Additionally, we cannot 215 
comment on the colonizing serotypes of the mothers. However, the fact that the 216 
antibody against the major GBS serotypes was detected in all women suggests prior 217 
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colonisation with GBS. Finally, we cannot comment on protective levels of antibody 218 
in this population, as there were no cases of GBS disease in our cohort. 219 
 220 
In summary, the decreased concentration of serum IgG that bound to the surface of 221 
GBS in HIV-infected women and their infants compared with non HIV-infected dyads 222 
is not due to a selective defect in the generation of GBS-specific IgG2 antibody. 223 
Future efforts should address enhancing protective antibody concentrations through 224 
maternal vaccination against GBS during pregnancy to optimise IgG2 concentration 225 
in the neonate.  226 
 227 
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Figure 1 Anti-GBS subclass distribution in HIV-infected and HIV-uninfected mothers 325 
and their uninfected infants at birth 326 
 327 
Legend: ST=serotype, HIV-=HIV-uninfected; HIV+=HIV-infected; SU/mL=standard 328 
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units per milliliter; IgG=immunoglobulin G. 329 
Horizontal bars compare groups, *p<0.05330 
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Table 1 – GMC Transplacental transfer ratios of total and subclass IgG1, IgG2, IgG3 and IgG4 against GBS STIa, III and V in HIV-infected and 331 
HIV-uninfected mothers to their infants [95% confidence interval (CI)]. 332 
 333 
STIa STIII STV 
 HIV+ HIV- p HIV+ HIV- p HIV+ HIV- p 
Total 1.1 (0.8-1.6) 1.0 (0.6-1.6) 0.75 0.6 (0.3-1.1) 1.3(0.8-2.3) 0.04 1.2 (0.7-1.6) 2.0 (1.1-3.0) 0.04 
IgG1 1.0 (0.7-1.5) 1.4 (1.0-2.0) 0.44 0.4 (0.1-1.4) 1.3 (0.7-2.5) 0.04 1.0 (0.7-1.4) 1.4 (0.9-2.1) 0.14 
IgG2 0.9 (0.5-1.5) 0.7 (0.5-1.2) 0.43 1.1 (0.4-3.2) 0.8 (0.4-1.4) 0.38 0.7 (0.5-1.1) 0.8 (0.6-1.1) 0.59 
IgG3 0.3 (0-9) 1.0 (0.3-3.3) 0.5     0.9(0.6-1.4) 1.3(0.8-2.1) 0.23 
IgG4 0.5(0.2-1.1) 1.6(0-4) 0.08    1.2(0.5-2.9) 0.6(0.3-1.4) 0.31 
Legend: ST=serotype; HIV+=HIV-infected; HIV-=HIV-uninfected; IgG=immunoglobulin G  334 
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